Page 2 - Graft Versus Host News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Graft versus host. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Graft Versus Host Today - Breaking & Trending Today

Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)

Takeda (TSE:4502/NYSE:TAK) today announced late-breaking data from the Phase 3 GRAPHITE study presented at the 2023 Tandem Meetings, demonstrating vedolizumab achieved a statistically significant and clinically meaningful improvement in lower gastrointestinal (GI) aGvHD-free survival by Day 180 after allo-HSCT with no relevant differences in safety profile versus placebo.1 ....

United States , Bin Chen , John Cunningham , Jun Saito , Cancer Center , International Blood Marrow Transplant Research , Hematopoietic Cell Transplant Therapy Program , Exchange Commission , European Union , European Medicines Agency , Takeda Pharmaceutical Company Limited , Met Its Primary Efficacy Endpoint , Clinically Meaningful Intestinal , Free Survival , New Safety Signals Were Seen , Vedolizumab Compared , Patients Who Received , Were Presented , Late Breaking Abstract , Cellular Therapy Meetings , American Society , Cellular Therapy , International Blood , Marrow Transplant Research , Yi Bin Chen , Hematopoietic Cell Transplant ,

Study gives explanation for severe graft-versus-host disease

Researchers revealed that alterations in the gut microbiome are connected to an increase in oxygen levels in the intestine that follows immune-mediated intestinal damage ....

United States , Pavan Reddy , University Of Michigan , Baylor Danl Duncan Comprehensive Cancer Center , Danl Duncan Comprehensive Cancer Center , Graft Versus Host , Ews India ,

BioSenic provides update on its autoimmune disease platform based on ATO

BIOSENIC Euronext Brussels and Paris: BIOS), the company specialized in serious autoimmune inflammatory diseases and cell repair, today announces an update on its systemic autoimmune disease. | November 9, 2022 ....

United States , Dana Farber Cancer Institute , France General , Francois Rieger , Corey Cutler , Catherine Haquenne , Ann Reum , Medsenic Biosenic , Harvard Medical School , Stem Cell Transplantation Program , Euronext Brussels , Host Disease , Arsenic Trioxide , Farber Cancer Institute , Graft Versus Host , Market Access , Chronic Graft , Systemic Lupus , Systemic Sclerosis , News Publishing , Biosenic Sa Stock Exchange , Press Release , Utoimmune Bios Be0974280126 ,

BioSenic SA provides update on its autoimmune disease

REGULATED INFORMATION The autoimmune disease platform has completed a successful phase IIb trial targeting cGVHD (chronic Graft vs Host Disease), with a. ....

Mont Saint Guibert , Waals Gewest , France General , Pierre Laurent , Medsenic Biosenic , Arthur Rouill , Bert Bouserie , Corey Cutler , Neil Hunter Michelle Boxall , Louis Victor Delouvrier , Ann Reum , Ib Communications , Newcap Investor Relations Financial Communications , Harvard Medical School , International Media Enquiries , Host Disease , Euronext Brussels , Bone Therapeutics , Arsenic Trioxide , Stem Cell Transplantation Program , Dana Farber Cancer Institute , Harvard Medical , Graft Versus Host , Market Access , Chronic Graft , Systemic Lupus ,

Nuvalent Appoints Michael L. Meyers, MD, PhD, to Board of Directors

/PRNewswire/ Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically. ....

New York , United States , Memorial Sloan Kettering Cancer Center , United Kingdom , Michaell Meyers , James Porter , Nuvalent Inc , Prnewswire Nuvalent Inc , Medicine At Columbia Presbyterian Medical Center , Company Quarterly Report On Form , Us Oncology Medical Affairs , Albert Einstein College Of Medicine , Aventis Pharmaceuticals Inc , Plough Research Institute , Exchange Commission , Syndax Pharmaceuticals Inc , Senior Clinical Advisor , Chief Executive Officer , Senior Vice President , Chief Development Officer , Chief Medical Officer , Syndax Pharmaceuticals , Graft Versus Host , Vice President , Clinical Leader , Oncology Scientific Innovation ,